Abstract: The invention relates to the treatment of various injuries, disorders, dysfunctions, diseases, and the like with MAPCs, without the need for adjunctive immunosuppressive treatment.
Abstract: The present disclosure provides a model of human fibrolamellar hepatocellular carcinoma (FL-HCC) cells maintained as a transplantable tumor line in a host and a method to establish a transplantable human FL-HCC tumor line. Methods of ex vivo cultures of the FL-HCC are provided. Methods of diagnosing and treating FL-HCC tumors are also provided.
Type:
Grant
Filed:
June 18, 2018
Date of Patent:
March 19, 2024
Assignee:
University of North Carolina at Chapel Hill
Abstract: Masked chimeric antigen receptor (CAR) constructs comprising an extracellular antigen binding domain specific tyrosine-protein kinase-like 7 (PTK7), which is linked to a mask peptide that blocks binding of masked CAR from binding to PTK7. Also provided herein are genetically engineered T cells expressing a masked CAR specific to PTK7 and therapeutic uses thereof.
Type:
Grant
Filed:
May 6, 2021
Date of Patent:
March 12, 2024
Assignee:
CRISPR THERAPEUTICS AG
Inventors:
Jason Sagert, Jui Dutta-Simmons, Jonathan Alexander Terrett
Abstract: The invention relates to a method for culturing a subpopulation of circulating epithelial tumour cells from a body fluid of a human or animal suffering from an epithelial tumour, wherein cells contained in the body fluid each containing at last one cell nucleus are separated from the body fluid and cultured over at least 24 hours in suspension, with formation of spheroids.
Abstract: Provided are in-vitro methods and devices for sustaining a synchronized circadian rhythm in cells of a cell culture by exposing the cells to a continuous flow of medium and to at least two stimuli provided in an oscillating manner with a periodicity of 24±4 hours, wherein a first stimulus and a second stimulus of said at least two stimuli are distinct, wherein said first stimulus is provided in a first time period and reaches a first peak in a first peak time period, and wherein a second stimulus is provided in a second time period and reaches a second peak in a second peak time period, and wherein an interval between end of time period of said first peak and beginning of said time period of said second peak is at least about 2 hours.
Type:
Grant
Filed:
June 19, 2020
Date of Patent:
February 27, 2024
Assignee:
Yissum Research Development
Company of the Hebrew University of Jerusalem Ltd.
Abstract: Provided is a method and a composition for improving behavioral performance in an individual comprising identifying an individual in need of treatment, and providing such an individual a composition comprising bacteria within the genus Bacteroides.
Type:
Grant
Filed:
July 22, 2020
Date of Patent:
February 13, 2024
Assignee:
California Institute of Technology
Inventors:
Sarkis K Mazmanian, Paul H Patterson, Janet Chow, Elaine Hsiao, Sara W McBride
Abstract: A single dissolving compound forms plural azeotropes, which can be azeotropically vaporized off at various stages of the treatment process, thus maintaining predictable concentrations of the chemicals present. The treatment process can be performed in the absence of formalin or related compounds which can interfere with the preservation of genetic material. A process for preserving a specimen includes using a dissolving compound that can form a plural number of azeotropes, at least one azeotrope being formed between one or more components of the dissolving compound and specimen-supplied water, and at least one azeotrope being formed between different components of the dissolving compound; successively and azeotropically vaporizing off formed azeotropes; and impregnating the specimen with a support medium.
Abstract: Various aspects and embodiments disclosed herein relate generally to the modelling, treatment, reducing resistance to the treatment, prevention, and diagnosis of a condition/disease associated with insufficient quantity and/or quality of hematopoietic stem cells (HSCs) and differentiated blood cells thereof. Embodiments include compositions and methods for treating the condition/disease, comprising the step of providing to a subject at least one therapeutically effective dose of a composition disclosed herein. Other embodiments include methods for generating and/or collecting hematopoietic stem cells from a subject.
Type:
Grant
Filed:
June 15, 2018
Date of Patent:
January 30, 2024
Assignee:
Indiana University Research and Technology Corporation
Inventors:
Hal Edward Broxmeyer, Maegan Lynn Capitano, Scott Harrison Cooper, Qingchun Cai
Abstract: Described herein are methods and compositions for producing modified, PD-L1 expressing hematopoietic stem cells, and uses thereof. Aspects of the invention relate to modulating the expression of micro RNA that controls the expression of PD-L1 in the hematopoietic stem cell. Methods for modulating the expression of micro RNA include, e.g., introducing to the cell a nucleic acid encoding a given micro RNA, or an agent that inhibits a given micro RNA.
Type:
Grant
Filed:
September 21, 2018
Date of Patent:
January 23, 2024
Assignee:
THE CHILDREN'S MEDICAL CENTER CORPORATION
Abstract: The present invention relates to an in vitro culture of haematopoietic cells, wherein said haematopoietic cells differentiate to form granulocytes characterised by the ability to kill cancer cells. The invention also relates to said granulocytes, methods for identifying said haematopoietic cells and granulocytes, compositions and kits comprising the same, as well as uses of the same for treating cancer.
Abstract: A single-chain variable fragment (ScFv) derived from anti-c-Met monoclonal antibody MetMAb that specifically binds to c-Met receptor is provided. Also provided are chimeric antigen receptor (CAR) vectors including the ScFv, human T cells transduced with the disclosed CAR vectors, pharmaceutical compositions including the CAR T cells, ScFv fusion proteins, and methods of treating a c-Met-positive cancer or a cancer characterized by overexpression of c-Met in a subject in need thereof by administering an effective amount of the disclosed CAR T cells.
Type:
Grant
Filed:
November 2, 2020
Date of Patent:
January 9, 2024
Assignee:
EAST TENNESSEE STATE UNIVERSITY RESEARCH FOUNDATION
Abstract: The present invention may provide a method for producing induced pluripotency stem cell-derived mesenchymal stem cells (IFN?-iMSC) pretreated with interferon-gamma; induced pluripotency stem cell-derived mesenchymal stem cells pretreated with interferon-gamma prepared by the method; a pharmaceutical composition for preventing or treating skin diseases, and a cosmetic composition for preventing or improving skin diseases, comprising culture thereof or exosome (IFN?-iMSC-exo) isolated therefrom as an active ingredient. When the composition of the present invention is used, it is possible to provide a composition for skin diseases and a stem cell therapeutic agent, which have an improved immunomodulating function over conventional mesenchymal stem cells.
Type:
Grant
Filed:
January 7, 2019
Date of Patent:
January 9, 2024
Assignees:
THE ASAN FOUNDATION, UNIVERSITY OF ULSAN FOUNDATION FOR INDUSTRY COOPERATION
Abstract: Disclosed are renal tissues and arrays thereof that include a layer of renal interstitial tissue, the renal interstitial tissue comprising renal fibroblasts and endothelial cells; and a layer of renal epithelial tissue, the renal epithelial tissue comprising renal tubular epithelial cells, the renal epithelial tissue in contact with the layer of renal interstitial tissue to form a three-dimensional, engineered, biological renal tissue. Also disclosed are methods of fabricating and using the same.
Type:
Grant
Filed:
March 25, 2021
Date of Patent:
January 9, 2024
Assignee:
ORGANOVO, INC.
Inventors:
Deborah Lynn Greene Nguyen, Shelby Marie King, Sharon C. Presnell
Abstract: The present invention relates to a process of converting carbon dioxide using a combination of a carbon dioxide mineralization and the metabolism of sulfur-oxidizing microorganisms. According to the process, a carbonate produced in the carbon dioxide mineralization reaction can be converted to a useful substance without supplying an external additional energy source (light, electrical energy, etc.) and mineral resources (metal ions). In addition, the process can be continuously performed by recycling metal ions necessary for the carbon dioxide mineralization reaction.
Type:
Grant
Filed:
September 26, 2017
Date of Patent:
December 19, 2023
Assignee:
SK Innovation Co., Ltd.
Inventors:
Woo Chan Park, Kwang Kuk Cho, Taewan Kim, Yeon Hwa La, Jayoung Ryu, Sang Min Lee
Abstract: The present invention is concerned with a composition and in vitro method for generating a desired cell type and/or tissue type from hair follicular stem cells. The composition and in vitro method are particularly suitable for generating an autologous desired cell type and/or tissue type. Furthermore, the composition and method are especially efficient and suitable for use in the context of cosmetic cell and/or tissue transplantation in recipient areas of a subject experiencing cell and/or tissue loss caused by, for example, a wound, scar, burn injury, tissue degeneration, and aging. The composition and in vitro method are also suitable to circumvent complications related to infections and/or immune rejection of a cosmetic cell and/or tissue implant or graft.
Abstract: The present invention relates to a pharmaceutical composition for preventing or treating neonatal hypoxic ischemic encephalopathy (HIE), comprising thrombin-treated stem cells or exosomes derived therefrom as an active ingredient, and a method for producing the same. According to the present invention, the thrombin-treated stem cell or the exosome derived therefrom has an increased expression of growth factors, immunoregulatory factors, antioxidation factors, or regeneration factors compared to a group not treated with thrombin and also enhances a neuronal apoptosis inhibitory effect, and thus has an advantage in that the therapeutic effect thereof on neonatal hypoxic ischemic encephalopathy (HIE) is excellent.
Type:
Grant
Filed:
October 31, 2017
Date of Patent:
December 5, 2023
Assignee:
MEDINNO INC.
Inventors:
Yun Sil Chang, Won Soon Park, So Yoon Ahn, Dong Kyung Sung
Abstract: The present invention relates to a method of producing cancer stem cells that comprises culturing a living cell population containing cancer cells in the presence of a gel substance to obtain a living cell population containing cancer stem cells, wherein the gel substance is a material that induces expression of osteopontin in at least a portion of cells contained in the living cell population. Moreover, the present invention relates to an agent for inducing conversion of cancer cells to cancer stem cells that comprises a gel substance that induces expression of osteopontin in at least a portion of the cells contained in a living cell population. The gel substance is a synthetic polymer gel composed of, for example, double network gel, PNaSS gel, PCDME gel, PA gel, RAMPS gel, PDMA gel or PAAc gel. The present invention provides means and a method that enable the preparation of cancer stem cells in a relatively short period of time and at a relatively low culturing cost without requiring expensive equipment.
Abstract: The present invention provides methods of classifying cluster of differentiation (CD) marker phenotype for hematopoietic cancer cells using multiple circulating cell-free CD markers in bodily fluid. In other aspects, treatment and disease progression of particular hematopoietic cancers can be monitored by measuring the levels of CD and other markers in bodily fluids of a patient.
Abstract: An umbilical cord mesenchymal stem cells (MSCs) and culture method and application thereof, which comprises an MSCs culture step comprising the following substeps: primary culture: culturing Wharton's jelly of an umbilical cord in a serum-free medium under a hypoxic condition; subculture: collecting P1 primary cells to prepare a single cell suspension which is centrifuged to obtain a cell pellet; adding a serum-free medium to the cell pellet, culturing under a hypoxic condition until passage, and continuously culturing up to P2-P3; adding a ligustrazine hydrochloride and a Shenmai injection during each subculture, digesting cells grown to a predetermined fusion degree, and collecting the cells cultured to P6; phenotypic test: testing the phenotype of the collected cells for later use. An MSCs preparation cultured by the method reduces easy aggregation of stem cells, thus avoiding cell adhesion, rouleau formation of red cells and cell cluster embolism after intravenous infusion into human bodies.
Type:
Grant
Filed:
April 29, 2020
Date of Patent:
November 21, 2023
Assignee:
FOSHAN JINGZHUN JIEN HEALTH MANAGEMENT CONSULTING CO., LTD.